Gries Financial LLC Invests $212,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

Gries Financial LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 637 shares of the company’s stock, valued at approximately $212,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swedbank AB lifted its holdings in shares of Medpace by 245.5% during the 4th quarter. Swedbank AB now owns 77,400 shares of the company’s stock valued at $25,715,000 after buying an additional 55,000 shares during the period. R Squared Ltd bought a new position in Medpace in the fourth quarter valued at about $30,000. Pacer Advisors Inc. lifted its holdings in Medpace by 40.8% in the fourth quarter. Pacer Advisors Inc. now owns 12,485 shares of the company’s stock valued at $4,148,000 after acquiring an additional 3,616 shares during the period. Blue Trust Inc. boosted its position in Medpace by 21.5% in the fourth quarter. Blue Trust Inc. now owns 808 shares of the company’s stock worth $270,000 after purchasing an additional 143 shares during the last quarter. Finally, Marshall Financial Group LLC bought a new stake in shares of Medpace during the 4th quarter valued at about $857,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 2.0 %

NASDAQ MEDP opened at $350.04 on Friday. The business has a 50-day moving average price of $342.11 and a 200-day moving average price of $353.38. The firm has a market cap of $10.88 billion, a price-to-earnings ratio of 30.65, a price-to-earnings-growth ratio of 1.77 and a beta of 1.36. Medpace Holdings, Inc. has a twelve month low of $286.76 and a twelve month high of $459.77.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Redburn Atlantic began coverage on shares of Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective on the stock. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday. Finally, TD Cowen decreased their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.